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Anneli Kari3, Outi K. T. Tammela4, Ulla Sankilampi5, Liisa Lehtonen6, Riitta H. Marttila1,2, Dirk 
Bassler7, Christian F. Poets8, Thierry Lacaze-Masmonteil9, Claude Danan10,11,12, Christophe 
Delacourt10,13,14, Aarno Palotie15,16,17,18,19,20, Louis J. Muglia  21, Pascal M. Lavoie22, Alice 
Hadchouel10,13,14, Mika Rämet1,2,23 & Mikko Hallman1,2
Bronchopulmonary dysplasia (BPD), the main consequence of prematurity, has a significant 
heritability, but little is known about predisposing genes. The aim of this study was to identify gene loci 
predisposing infants to BPD. The initial genome-wide association study (GWAS) included 174 Finnish 
preterm infants of gestational age 24–30 weeks. Thereafter, the most promising single-nucleotide 
polymorphisms (SNPs) associated with BPD were genotyped in both Finnish (n = 555) and non-Finnish 
(n = 388) replication cohorts. Finally, plasma CRP levels from the first week of life and the risk of BPD 
were assessed. SNP rs11265269, flanking the CRP gene, showed the strongest signal in GWAS (odds 
ratio [OR] 3.2, p = 3.4 × 10−6). This association was nominally replicated in Finnish and French African 
populations. A number of other SNPs in the CRP region, including rs3093059, had nominal associations 
with BPD. During the first week of life the elevated plasma levels of CRP predicted the risk of BPD (OR 
3.4, p = 2.9 × 10–4) and the SNP rs3093059 associated nominally with plasma CRP levels. Finally, SNP 
rs11265269 was identified as a risk factor of BPD (OR 1.8, p = 5.3 × 10−5), independently of the robust 
antenatal risk factors. As such, in BPD, a potential role for variants near CRP gene is proposed.
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Bronchopulmonary dysplasia (BPD) is a major complication of prematurity. In the USA alone, about 10,000–
15,000 new cases are diagnosed each year1. The potential adverse consequences of BPD include asthma and 
chronic obstructive pulmonary disease (COPD)2–4. Effective prevention of BPD does not exist, and even with 
modern state-of-the-art therapies the incidence has not fallen1.
In BPD, poor alveolarization and disrupted pulmonary vascularization lead to impaired gas exchange, clini-
cally seen as prolonged need for respiratory support5. Inflammation plays a key role in the pathogenesis of BPD, 
but the molecular mechanisms remain unknown6, 7. According to studies in twins, genetic factors account for 
53–82% of the variance in susceptibility to BPD8, 9. However, identification of predisposing genes has been chal-
lenging. Although a suggestive association between SPOCK2 gene and BPD was discovered in the first pub-
lished genome-wide association study (GWAS) on BPD10, two subsequent GWASs did not reveal any significant 
associations at the genome-wide level11, 12. Moreover, candidate gene studies have been largely unsuccessful at 
producing replicable results13, 14. One probable reason for this “missing heritability” is the heterogeneity of study 
populations. In Hadchouel et al.’s study, the infants were of either Caucasian or African origin. Wang et al.’s pop-
ulation consisted of four identified ethnic groups, and Ambalavanan et al.’s study included both Caucasians and 
African-Americans. Different ethnic groups differ in their allele frequencies, thus complicating genetic analyses.
The population of Finland is genetically relatively homogeneous and has therefore been used extensively in 
genetic studies15, 16. Furthermore, neonatal practices vary little in Finland due to standardized treatment pro-
tocols. This is of importance when studying a trait such as BPD, the incidence of which is affected by neonatal 
treatment practices.
In the present investigation, we conducted a GWAS on BPD in a Finnish population. To make the results 
more generalizable, we studied two replication populations from Finland and two populations from Canada and 
France. We identified a single nucleotide polymorphism (SNP), rs11265269, as an independent risk factor of BPD.
Methods
Study design and study populations. A flow chart of the study is shown in Fig. 1. The total numbers of 
BPD cases and controls in the entire study were 319 and 798, respectively.
Inclusion criteria for all infants included in the study were (1) gestational age (GA) <31 wk and (2) no major 
congenital malformations. The discovery population used for the GWAS (step 1 of the study, n = 174) and the two 
internal replication populations (first internal replication, step 2 of the study, n = 326 and second internal replica-
tion, step 4 of the study, n = 229) consisted of Finnish infants collected prospectively at the five university hospi-
tals in Finland. The external replication populations (step 3 of the study, n = 388) comprised infants from Canada 
and France. To augment the power of the GWAS study, two control infants were chosen for each BPD case. Only 
one infant from each sibling pair was selected. For details of patient selection, see Supplementary Information. 
Clinical characteristics of the population in the GWAS are shown in Table 1, and those of the replication popu-
lations are shown in Supplementary Tables S1 and S2. The study was approved by the Ethics Committee of Oulu 
University Hospital, the University of British Columbia Clinical Research Ethics Board, the University of Alberta 
Ethics Board, and the Comités de Protection des Personnes (CPP) Ile de France VI and IX. Written informed 
consent was obtained from the infants’ parents. All experiments were performed in accordance with relevant 
guidelines and regulations.
Diagnostic criteria for BPD. BPD was defined as a continuing need for supplemental oxygen or positive 
pressure support (including high-flow 5–6 litre per minute via nasal probes) at 36 wks. postmenstrual age (PMA); 
i.e., moderate-to-severe BPD according to National Institute of Child Health and Human Development (NICHD) 
criteria17. This criterion was based on twin studies, in which moderate-to-severe BPD is significantly affected by 
genetic factors whereas mild BPD is not9. The controls were infants without BPD or with mild BPD. According to 
NICHD criteria, mild BPD is defined as a need for supplementary oxygen or positive pressure support at the age 
of 28 days but no longer at the age of 36 wks. PMA. No BPD is defined as no need for supplementary oxygen or 
positive pressure support at the age of 28 days.
Figure 1. Flow chart of the study.
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Statistical analyses and outline of other methods. Specific details of statistical analyses, genotyping, 
data processing, imputation and selection of SNPs for replication analyses, and analyses of CRP values, are shown 
in Supplementary Information. Information about DNA sample preparation is shown in Supplementary Table S3.
Genome-wide SNP genotyping was performed with the Infinium HumanCoreExome BeadChip (Illumina, 
San Diego, CA, USA). GWAS was used to identify SNPs associated with moderate-to-severe BPD; data processing 
and statistical analyses were performed with PLINK, v. 1.07 or 1.0918. After quality control, 276,306 SNPs with 
minor allele frequency >0.01 remained for GWAS. We used a filtering strategy to narrow down the SNPs ana-
lyzed for association with BPD in each step (Fig. 1): the most promising GWAS SNPs were analyzed in the inter-
nal Finnish replicate, and the most consistent SNPs were further analyzed in two external populations (Caucasian 
and French African). At the final step, four SNPs were analyzed in the second internal Finnish replicate. Logistic 
regression under the additive model with GA as a covariate was used to assess associations with BPD in these 
populations. The SNP selection criteria are listed in the Supplementary Information. At the final stage, we also 
included small-for-gestational age (SGA, Z-score ≤−2 SD) as a covariate in a logistic regression model to assess 
how the significant antenatal factors together (GA and SGA) with the SNP with most consistent signal affect the 
risk of BPD.
Because the SNP with most consistent signal was located near the CRP gene, we analyzed plasma CRP levels 
for association with BPD and SNP genotypes. Daily CRP levels were available because of the current practice in 
screening for infection during the first week after very premature birth. The infants included in the plasma CRP 
studies were a subset of the populations analyzed in the GWAS and the first internal replicate; infants for whom 
CRP levels could be recorded were included (n = 275; 112 infants from GWAS, 163 infants from first internal 
replicate). Logistic regression was used to evaluate whether SNP genotypes were associated with maximum and 
mean CRP level (CRP values above/below median) during the first week of life with PLINK, v. 1.0918. The num-
ber of surfactant doses was included as a covariate, because this variable associated with CRP levels (p < 0.001). 
Association of the BPD incidence or SNP genotypes with CRP levels was assessed by the χ2 or Kruskal–Wallis test 
with SPSS Statistics 20.0, IBM Corporation. At the final phase, logistic regression with SPSS was used to evaluate 
whether CRP levels are significant predictors of BPD using GA and SGA as covariates.
Results
Associations in GWAS. The GWAS was performed in a discovery cohort of 60 cases with moderate-to-se-
vere BPD and 114 controls. GA, gender, proportion of singletons, exposure to antenatal or postnatal steroids or 
to clinical chorioamnionitis did not differ between the cases and controls. As expected19, 20, both birth weight 
and birth-weight Z-score were lower in BPD cases compared with controls, suggesting a lower foetal growth rate 
among BPD infants. Pre-eclampsia was more common in the BPD group (Table 1).
In the GWAS, none of the SNPs reached our stringent genome-wide significance level (p < 1.8 × 10−7), but 
there were many suggestive associations (Supplementary Figure S1). Results for the SNPs with the strongest 
suggestive signals (p < 1 × 10−4) are shown in Table 2. The most promising SNP was rs11265269 (odds ratio 
[OR] 3.22, p = 3.43 × 10−6), which is located between the CRP and DUSP23 genes (approximately 44 and 23 kb 
upstream of each gene, respectively). Population stratification was minimal (Supplementary Figure S2). The 
imputed SNPs did not show any association signals that were clearly more significant than those of the genotyped 
SNPs (Supplementary Figure S3). The SNPs with p < 5 × 10−4 in the GWAS were selected for further genotyping, 
and are listed in Supplementary Table S4.
Association of rs11265269 with BPD in replication populations. First, we chose 155 SNPs for 
analysis in the 1st internal replication population (105 cases and 221 controls) (Supplementary Table S1). These 
SNPs were selected on the basis of the strongest signals in GWAS; in addition, previously BPD-associated SNPs 
Characteristics BPD cases Controls p
Total n 60 114
Moderate/severe BPD, n (%) 33/27 (55.0/45.0)
No BPD/mild BPD, n (%) 64/50 (56.1/43.9)
GA, weeks*,† 27.1 ± 1.8 (24.1–30.9) 27.5 ± 1.7 (23.3–30.9) 0.114
GA < 28 wk, n (%) 42 (70.0) 66 (57.9) 0.118
Birth weight, grams* 865 ± 244 (440–1470) 1017 ± 264 (520–1695) 2.85 × 10–4
Birth weight Z-score*‡ −1.5 ± 1.34 (−4.0–1.1) −0.9 ± 1.20 (−4.1–1.6) 3.00 × 10−3
SGA, n (%) 23 (38.3) 20 (17.5) 3.00 × 10−3
Male gender, n (%) 32 (53.3) 57 (50.0) 0.676
Singletons, n (%) 57 (95.0) 105 (92.1) 0.474
Antenatal steroids, n (%) 57 (95.0) 108 (94.7) 0.941
Preeclampsia, n (%) 23 (38.3) 24 (21.1) 0.046
Chorioamnionitis§ 15 (26.8) 38 (34.5) 0.311
Table 1. Clinical characteristics of the study population in the genome-wide association study of 
bronchopulmonary dysplasia. Definition of abbreviations: BPD, bronchopulmonary dysplasia; GA, gestational 
age; SD, standard deviation; SGA, small for gestational age (Z-score ≤−2 SD). *Mean ± standard deviation 
(range). †GA defined on the basis of foetal ultrasound before 15 weeks of pregnancy. ‡Birthweight Z-score 
describes distribution of birthweight at given length of gestation in SD. §Data not available for eight infants.
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with consistent signals were included. The selection criteria are given in detail in Supplementary Information. 
Thereafter, the top 41 SNPs, based on GWAS results and 1st internal replication, were further analysed in the 
external replication populations (Caucasian, n = 312, and French African, n = 76) (Supplementary Table S2 
and Supplementary Information). Finally, to increase power and to validate the most promising associations, 
SNPs rs11265269 (the top SNP identified by GWAS, near CRP/DUSP23), rs1889268 (COL15A1) and rs5999125 
(LARGE) were genotyped in a second internal replication population (Finnish, n = 229). Of all the SNPs ana-
lysed in the external replication populations, these three SNPs showed the most consistent results and were 
thus selected for this final genotyping step. Because GA was significantly different between cases and controls 
in the replication populations, the analyses were performed using logistic regression (LR) analysis with GA as a 
covariate.
In the first internal replicate (Supplementary Table S4), only one SNP, rs6690148, showed nominal associa-
tion with BPD (p  < 0.05). The top SNP in GWAS, rs11265269 showed an effect similar to that detected in GWAS 
(OR 1.42, p = 0.097). Of the SNPs analysed further, two showed nominal association in the external replication 
populations: rs11265269 in the French African population and COL15A1 SNP (rs1889268) in the Caucasian pop-
ulation (Supplementary Table S5). Overall, SNP rs11265269 (the SNP with the strongest signal in GWAS) was the 
most consistent SNP. Table 3 summarizes the results for this SNP in all the replication populations. In addition 
to the nominal replication in the French African population, this SNP associated with BPD when the internal 
replication populations were combined (p = 0.029). With all of the Finnish populations combined, the OR for the 
minor allele of SNP rs11265269 was 1.84 (p = 2.39 × 10−5) (Table 3); i.e., the effect was smaller than in the initial 
GWAS, which may be due to overestimated effect size in GWAS. The case–control allele frequency differences for 
the COL15A1 SNP (rs1889268) were also consistent in all Caucasian populations, although the difference was not 
significant in the internal replication populations (Supplementary Tables S5 and S6). The results for the LARGE 
SNP information GWAS
SNP* Chr Position† Gene‡
Case/Control minor 
allele frequency OR p
rs11265269 1 159,728,127 CRP, DUSP23 0.392/0.167 3.22 3.43 × 10−6
rs1481294 11 38,604,075 LOC103312105, LOC105376635 0.325/0.575 0.36 9.56 × 10−6
rs2351857 7 137,467,829 DGKI 0.617/0.373 2.71 1.42 × 10−5
rs11691168 2 74,999,114 LOC102724482 0.475/0.250 2.71 2.13 × 10−5
rs2149564 9 98,607,989 LINC00476 0.642/0.404 2.65 2.39 × 10−5
rs6562965 13 77,351,486 LOC105370265 0.442/0.224 2.75 2.42 × 10−5
rs11745686 5 74,198,611 LOC105379039, FAM169A 0.400/0.193 2.79 3.15 × 10−5
rs1403617 3 165,255,278 LINC01322, BCHE 0.475/0.254 2.65 3.20 × 10−5
rs12788032 11 38,632,770 LOC103312105, LOC105376635 0.275/0.504 0.37 3.89 × 10−5
rs1822471 15 79,327,227 RASGRF1 0.092/0.281 0.26 4.57 × 10−5
rs9552800 13 23,599,673 LOC105370111, SGCG 0.242/0.083 3.51 4.67 × 10−5
rs17537018 5 155,458,803 SGCD, LOC105377674 0.367/0.171 2.81 4.70 × 10−5
rs2527506 7 2,968,361 CARD11 0.325/0.140 2.95 4.85 × 10−5
rs4704970 5 155,500,992 SGCD, LOC105377674 0.358/0.167 2.79 5.78 × 10−5
rs1358603 7 52,757,480 LOC105375280, LOC101928257 0.617/0.390 2.51 5.78 × 10−5
rs4506388 23 130,210,648 ARHGAP36 0.534/0.281 2.94 6.13 × 10−5
rs9979500 21 48,029,698 S100B, PRMT2 0.450/0.241 2.57 6.57 × 10−5
rs4640066 13 77,354,747 LOC105370265 0.475/0.263 2.53 7.00 × 10−5
rs2352931 16 86,169,068 LOC105376778, LOC101928582 0.200/0.412 0.36 7.01 × 10−5
rs12603672 17 51,115,243 LOC105371831, LOC101927337 0.117/0.018 7.40 7.23 × 10−5
rs2279073 19 44,739,303 ZNF227 0.325/0.548 0.40 7.32 × 10−5
rs1044189 12 7,053,149 RNU7-1 0.383/0.189 2.67 7.57 × 10−5
rs7934284 11 38,577,786 LOC103312105, LOC105376635 0.608/0.386 2.47 7.67 × 10−5
rs200642524 8 10,470,709 RP1L1 0.067/0.000 — 8.00 × 10−5
rs11200206 10 123,635,883 ATE1 0.442/0.237 2.55 8.29 × 10−5
rs2543361 14 76,593,690 GPATCHL2L, IFT43 0.575/0.355 2.46 8.34 × 10−5
rs314277 6 105,407,662 LIN28B 0.275/0.110 3.08 8.35 × 10−5
rs4583363 18 65,162,006 DSEL, LOC643542 0.408/0.211 2.59 9.16 × 10−5
rs11178156 12 70,635,747 LINC01481, CNOT2 0.258/0.474 0.39 9.67 × 10−5
Table 2. Single-nucleotide polymorphisms showing suggestive association signals in the genome-wide 
association study of bronchopulmonary dysplasia. Definition of abbreviations: BPD, bronchopulmonary 
dysplasia; Chr, chromosome; GWAS, genome-wide association study; OR, odds ratio; SNP, single-nucleotide 
polymorphism. *SNPs with p < 1 × 10−4 in GWAS are shown. †Chromosomal positions refer to human genome 
build 37 (GRCh37/hg19). ‡Respective locus shown for SNPs within genes; two nearest loci shown for intergenic 
SNPs.
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SNP (rs5999125) were more inconsistent (Supplementary Tables S5 and S6). The results for the other SNPs ana-
lysed in the replication populations are listed in Supplementary Tables S4 and S5.
We reanalysed the three SNPs with the strongest signals (rs11265269, rs1889268 and rs5999125) in the Finnish 
populations by excluding the mild BPD infants from the controls. This exclusion did not notably alter the results 
(Supplementary Table S7). For rs11265269 the OR was 3.28 in GWAS (p = 5.94 × 10−5) and 1.79 in the joint anal-
ysis of all Finnish populations (p = 1.41 × 10−3). Altered treatment practices or changes in the diagnostics of BPD 
(Supplementary Information) could also influence the results. Therefore, the genetic data was reanalysed sepa-
rately for infants born during 1998–2010 and after 2010. During both time periods the association of rs11265269 
with the risk of BPD was maintained in GWAS (OR 4.78 and 2.37, respectively) and in joint analysis of all Finnish 
populations (OR 1.87 and 1.71, respectively).
SNPs previously associated with BPD: no clear association signals. Next, we analysed, first in 
our GWAS data, and thereafter the most promising SNPs in the internal replication population, the SNPs in 
proximity to genes that were previously found to be associated with BPD10, 11. Some of these SNPs showed a 
nominal association in the GWAS, but none were associated with BPD in the first internal replication popu-
lation (Supplementary Tables S8 and S9). Consistently, none of the SNPs in previously-associated genes that 
were analysed further associated with BPD in the Caucasian and French African external replication popula-
tions (Supplementary Table S10). Overall, SNP rs2536512 in SOD3 was the most promising. This SNP associated 
nominally with BPD in GWAS (OR = 0.53, p = 0.017), and showed a similar effect in the first internal repli-
cate (OR = 0.75, p = 0.173) and external Caucasian population (OR = 0.70, p = 0.072). SNP rs2536512 reached 
p < 0.05 when the Caucasian population was combined with the internal replication population. However, there 
was no association in the French African replicate or in the second internal replicate (Supplementary Table S10). 
With all the Finnish populations combined, this SNP had an OR of 0.76 (p = 0.060).
Evaluation of BPD risk and SNPs in the CRP region and in other regions previously associated 
with plasma CRP levels. Because SNP rs11265269 showed the most promising association with BPD and is 
located between DUSP23 and CRP genes, we investigated this genomic region in more detail. We determined that 
rs11265269 displays linkage disequilibrium (LD) with some of the SNPs within or flanking the CRP gene rather 
than those flanking the DUSP23 gene (Supplementary Figure S4, Fig. 2). This is consistent with 1000 Genomes 
data (http://www.1000genomes.org). Furthermore, some of the other SNPs in the vicinity of only CRP gene also 
showed association signals in GWAS. Because many SNPs in this region are known to be associated with serum 
CRP levels, we further analysed 13 SNPs in the region extending from 69 kb 5′ to 3 kb 3′ of CRP to capture all 
common variations within this region in the first internal replication population (Supplementary Table S11). 
In addition to rs11265269, two SNPs (rs3093059 and rs12091403) in this region showed p < 0.05 for associa-
tions with BPD when the first internal replication population was combined with the population analysed in the 
GWAS. Haplotype analysis in this region revealed that three haplotypes were associated with BPD (p < 0.05); 
these could be discriminated by the three SNPs with p < 0.05 in the single SNP analyses (Table 4, Fig. 2). SNP 
rs11265269 was the only one of these three SNPs nominally associated with BPD in the Finnish and French 
African replication populations (Supplementary Table S12).
Using our GWAS data, we also analysed 108 SNPs (23 SNPs near CRP and 85 SNPs in other genes) that were 
previously reported to be associated with CRP levels21–23. Some of the SNPs had nominal associations with BPD 
(p < 0.05). However, in addition to those in the CRP gene region (Supplementary Table S11), none of them ful-
filled our criteria to be included for genotyping in the replication sets.
SNPs in the CRP gene region and plasma CRP levels. Next, we analysed whether SNPs near the CRP 
gene are associated with plasma CRP levels during the first week of life. Altogether, 275 Finnish infants were 
included. CRP values were obtained from clinical laboratory reports. Infants carrying the BPD-predisposing 
Study population n
Case/control minor 
allele frequency* OR (95% CI) p
Internal replication 
population 1 (Finnish) 326 0.278/0.230 1.42 (0.94–2.13)
† 0.097
Internal replication 
population 2 (Finnish) 229 0.274/0.204 1.50 (0.75–2.86)
† 0.216
Internal replication 
populations combined 555 0.277/0.218 1.47 (1.04–2.06)
† 0.029
All Finnish populations 
combined 729 0.313/0.207 1.84 (1.39–2.45)
† 2.4 × 10–5
External replication 
population 1 (Caucasian) 312 0.263/0.259 0.90 (0.59–1.37)
† 0.629
External replication 
population 2 (French African) 76 0.440/0.235 2.48 (1.17–5.24)
† 0.017
Table 3. Association of single-nucleotide polymorphism rs11265269 with moderate-to-severe 
bronchopulmonary dysplasia. Definition of abbreviations: CI, confidence interval; OR, odds ratio. * Minor allele 
frequencies of the controls are similar to those of the populations of the 1000genomes project populations 
(0.239 and 0.223 for the European and African populations, respectively; http://www.1000genomes.org). †Odds 
ratio for minor allele under additive model in logistic regression analysis with gestational age as a covariate.
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alleles of SNPs rs11265269 and rs3093059 tended to have higher CRP levels than non-carriers. In LR analysis 
with the number of surfactant doses as the established significant covariate, SNP rs3093059 was associated with 
mean plasma CRP concentrations (p = 0.046) but not with maximum plasma CRP concentrations (p = 0.074) 
(Supplementary Table S13) during the first week of life. SNP rs11265269 did not show association.
Plasma CRP levels during the first week of life associated with BPD. Because the SNP with the 
strongest association signal in GWAS was located upstream of the CRP gene and other SNPs near CRP (including 
rs3093059) associated with plasma CRP levels in adult populations22, 23, and also showed nominal associations 
with BPD, we analysed whether maximum or mean CRP levels during the first week of life could predict develop-
ment of BPD. Available laboratory data from 275 Finnish preterm infants were studied.
Figure 2. Linkage disequilibrium plot for single-nucleotide polymorphisms (SNPs) within the region flanking 
rs11265269, the top SNP in genome-wide association study (GWAS) of bronchopulmonary dysplasia. Pairwise 
D′ values for each SNP pair in the combined Finnish population (discovery GWAS and first internal replicate) 
are shown. Darker colors indicate stronger linkage disequilibrium. Of the SNPs analysed, rs2794520 and 
rs3093059 (D′ 0.86 with rs11265269) are located down- and upstream of the CRP gene, respectively; these 
SNPs are known to be associated with plasma levels of CRP. SNP rs1129923 is located within the DUSP23 (dual 
specificity phosphatase 23) gene; rs7519478 and rs4233356 are up- and downstream of DUSP23.
Haplotype 
block* Haplotype
Case/control 
haplotype frequency† p
1 AGACG 0.335/0.355 0.522
AACCA 0.223/0.202 0.444
AAACG 0.146/0.186 0.122
AAACA 0.110/0.139 0.193
AAAAG 0.091/0.064 0.129
GAACA 0.092/0.049 8.2 × 10–3
2 GAA 0.385/0.473 8.8 × 10−3
AGA 0.281/0.308 0.383
GGG 0.324/0.210 9.1 × 10−5
3 AAGG 0.372/0.426 0.100
GGGA 0.252/0.232 0.499
GAAG 0.134/0.129 0.809
GGGG 0.137/0.123 0.529
GAGG 0.090/0.082 0.660
Table 4. Haplotype analysis within the region flanking rs11265269, the top single-nucleotide polymorphism 
(SNP) in genome-wide association study (GWAS) of bronchopulmonary dysplasia (BPD). *Haplotype blocks 
are illustrated in Fig. 2. Block 1 consists of SNPs rs3093059, rs3122012, rs2808635, rs11265263, and rs4285692 
adjacent to the CRP gene. Block 2 consists of SNPs rs4656849, rs12094103, and rs11265269. Block 3 consists 
of SNPs rs4604689, rs7519487, rs1129923, and rs4233356 encompassing the DUSP23 gene. BPD-predisposing 
alleles of SNPs rs3093059 and rs11265269 and protective allele of rs12091403 are underlined; they discriminate 
the haplotypes showing association (p < 0.05). †Frequency of haplotype in BPD cases and controls in the 
combined Finnish population (discovery GWAS and first internal replicate).
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Plasma levels of CRP before 12 hours’ age were mostly low; only 8.4% of the infants had a CRP concentration 
of more than 1 mg/L; the maximum was 53.4 mg/L. These plasma levels were not associated with the risk of BPD 
(p = 0.66). We next studied whether maximum and mean plasma CRP concentrations during the 1st week were 
associated with the risk of BPD. The median values of the maximum and mean CRP levels during the first week 
were 4.0 mg/L and 1.6 mg/L, respectively. The maximum plasma CRP concentration was above the median in 
72.6% of the BPD cases and in 40.6% of the controls (p = 3.0 × 10−6). Mean CRP levels during the 1st week of 
life exceeded the median in 74.0% of the BPD cases and 41.6% of the controls (p = 2.0 × 10−6) (Table 5). The 
number of surfactant doses given was associated with these CRP levels (p = 8.86 × 10−8 for the maximum and 
p = 3.25 × 10−8 for the mean level). In contrast, the length of gestation, prolonged rupture of membranes, cho-
rioamnionitis, cord blood pH or blood culture-proven sepsis (either early- or late-onset during the first week) 
showed no detectable association.
In LR analysis with GA and SGA as covariates, both the maximum CRP level during the first week and the 
mean CRP level during the first week were significant predictors of BPD, with ORs of 3.4 and 3.6, respectively 
(Table 5).
SNP rs11265269 in the CRP gene region is an independent risk factor of BPD. To consolidate the 
evidence on the role of rs11265269 as a risk factor of BPD, this SNP was analysed together with the significant 
antenatal risk factors, GA and SGA. Table 6 shows the results of LR analysis that included rs11265269 in the 
model. This SNP predicted the risk of BPD in each population, independently of the degree of prematurity and 
SGA status.
Discussion
BPD is a multifactorial disease with high heritability. We conducted a GWAS on a relatively genetically homog-
enous Finnish population and observed a suggestive association between moderate-to-severe BPD and SNP 
rs11265269 near the CRP gene. This association was replicated in an independent Finnish population and in 
population of infants of African descent from France. Furthermore, plasma levels of CRP during the first week of 
life predicted the development of BPD. Additionally, the known antenatal risk factors and rs11265269 additively 
predisposed to BPD. Finally, another SNP from the CRP-gene region, SNP rs3093059, associated with plasma 
CRP levels. No significant association was noted with the SNP rs11265269 and plasma CRP, however.
CRP is a prominent clinical marker of infections and inflammatory disease. Persisting inflammation is a major 
finding in infants developing BPD. Mechanical ventilation and hyperoxia are known postnatal risk factors for 
BPD and have been shown to induce inflammation24, 25. CRP is mainly produced in the liver. One of the main 
ligands of CRP is phosphocholine, a constituent of many bacterial and fungal polysaccharides. Phosphocholine is 
also present in dead or dying cells26. IL-6 and IL-1 have a major synergistic effect on the induction of CRP expres-
sion. High level of CRP activates phagocytic cells, stimulates production of inflammatory cytokines, regulates the 
classical complement pathway and may cause adverse vascular events when present in excess27.
The plasma levels of CRP are generally low at birth28, and a mechanism of deficient CRP synthesis in fetal liver 
has been proposed29. In present study, plasma levels of CRP before age 12 hours were mostly low and predicted 
neither BPD nor sepsis. By contrast, it was the increase in plasma CRP after birth and the maintenance of variably 
elevated CRP levels during the first week of life that discriminated between infants who will develop BPD and 
those who will not. This is in line with what earlier has been reported about CRP and BPD, namely that CRP on 
day 28 and BPD associated30, and that there was a qualitative association between CRP levels from days 0 to 21 
and BPD31. In present study, the association between CRP values and BPD was demonstrated already during the 
first week of life, which is of clinical importance. Our novel finding, that elevated plasma CRP values from the 
first week of life can be used as a biomarker for an increased risk of BPD, needs to be confirmed in independent 
studies. The clinical feasibility of CRP makes it superior to the other markers identified with an increased risk of 
BPD32. Noteworthy the CRP values did not correlate with either early- or late-onset sepsis. This is in consonance 
with what is known about CRP in the preterm i.e. that both the baseline level of CRP and the response to infection 
are lower in premature infants compared to the term new-borns. Also the sensitivity and specificity of CRP in 
diagnosing sepsis are lower at preterm neonates compared to their term peers33. As all other laboratory values, the 
interpretation of CRP requires the context of other findings and clinical signs of the patient.
Besides inflammation, infection and other environmental factors, genetic polymorphisms influence the 
expression of CRP. The heritability of plasma CRP is estimated to be 25–40%, and levels of CRP vary among dif-
ferent ethnic groups34, 35. Moreover, the SNPs reported to affect CRP levels vary among different populations23, 36. 
Variable*
BPD cases/
controls, n
BPD cases/controls with 
CRP above median, n (%)† OR (95% CI)‡ p‡
Maximum CRP 73/202 53 (72.6)/82 (40.6) 3.40 (1.76–6.58) 3.0 × 10−4
Mean CRP 73/202 54 (74.0)/84 (41.6) 3.57 (1.88–6.77) 9.7 × 10−5
Table 5. Association of plasma C-reactive protein (CRP) level with bronchopulmonary dysplasia (BPD). 
Definition of abbreviations: BPD, bronchopulmonary dysplasia; CI, confidence interval; CRP, C-reactive protein; 
OR, odds ratio. *Maximum or mean CRP level (mg/L) during the first week of life. In Finland, a CRP level of 
<3 mg/L is considered to be within the normal reference range, but no normative values for preterm infants 
are available. †χ2 test p values were 3.0 × 10−6 and 2.0 × 10−6 for maximum and mean CRP, respectively. ‡Logistic 
regression with gestational age and small-for gestational (SGA, defined as birthweight Z-score of ≤−2 SD) as 
covariates. Odds ratio given for maximum and mean plasma CRP (above/below median) during first week of life.
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As such, the lack of an association between rs11265269 and BPD in one of the external replication populations is 
not surprising. CRP response varies also between species and for instance in mice Crp has generally low expres-
sion levels37, thus complicating further confirmation of the findings of this study.
A strength of this study is the relative homogeneity of the population in the GWAS and in the internal replication 
sets. Because of the Finnish population history with a restricted number of founders, the allelic diversity in Finland is 
lower than in most other populations38. This compensates for the main limitation of the study, namely the small sam-
ple size in the GWAS. However, it is possible that the small sample size limits the overall generalization of our GWAS 
findings to other study populations. Another limitation is the lack of association between rs11265269 and plasma 
CRP levels. This SNP, however, is located in the same LD region with rs3093059 and other CRP-associated SNPs, and 
also haplotypes within the region associated with BPD. We propose that rs11265269 may show milder association 
with CRP plasma levels that remains undetected in our set of study subjects, or it may associate with the CRP syn-
thesis in lung cells39. Unfortunately, potentially valuable data on expression of CRP in lung compartments was not 
available. Further credence to association between rs11265269 and moderate-to-severe BPD is given by the finding 
that the association remained similar when infants with mild BPD were excluded from the controls. Furthermore, 
as altered treatment practices and changes in diagnostics may have influenced the results, we repeated the analyses 
in subgroups of infants born in two time periods (before and after 2010) and the association remained similar. It is 
also possible that the potential predisposing role of rs11265269 in BPD is linked to a gene other than CRP, such as 
DUSP23, the adjacent gene, encoding dual specificity phosphatase 23. DUSP23 is a phosphatase involved in regula-
tion of cell-cell adhesion40. Its potential link to BPD remains to be investigated.
Although none of the initial GWAS signals were consistently replicated in our replication populations, some 
of these may represent real association signals. As an example, of the SNPs suggestively associated with BPD in 
GWAS, those within RASGFR1 (encoding Ras protein specific guanine nucleotide releasing factor 1) may rep-
resent real associations, since other SNPs located near this gene showed association signals in a previous GWAS 
of BPD11. Furthermore, some of the other genes with suggestively associated SNPs could be biologically relevant 
for the BPD phenotype. As an example, variants near the SGCD gene (encoding sarcoglycan delta) are known 
to be associated with airway responsiveness, a process that is linked to decline in lung function in subjects with 
COPD41. Larger studies are required to assess the potential role of these genes in BPD.
Although the heritability of BPD is estimated to be high, consistent and statistically significant associations have 
not been detected in genomic studies. Current evidence suggests a multiplicity of genes and pathways involved in 
the pathogenesis of BPD. Besides GWAS, these pathways have been suggested in other large-scale studies, includ-
ing exome sequencing and transcriptomic studies. It is possible that rare predisposing variants detected by exome 
sequencing can explain part of the missing heritability of BPD; these rare variants would be missed with the GWAS 
strategy. In line with our present finding, CRP was one of the top five genes characterizing severe BPD compared 
to non-BPD infants in a recent exome sequencing study42. In another exome sequencing study, Li et al. tentatively 
identified 258 genes with rare nonsynonymous variants in patients with moderate-to-severe BPD. These genes rep-
resented pulmonary structure and function, morphogenesis of embryonic epithelium, and regulation of the Wnt 
signalling pathway43. On the other hand, Ambalavanan and co-workers combined a GWAS with pathway analysis 
and found evidence suggesting involvement of both known (phosphorus oxygen lyase activity) and new (targets of 
miR-219) pathways in the pathophysiology of BPD12. Bhattacharya et al. performed a genome-wide gene-expression 
study and reported evidence on accumulation of connective tissue inflammatory mast cells in the lungs of infants 
who died of BPD44. In addition to further exome and whole-genome sequencing studies to detect rare predisposing 
variants, additional approaches, such as meta-analyses, pharmacogenomics and experimental studies are required. 
Identification of BPD-predisposing genes would bring information about the pathogenesis of BPD, ultimately ena-
bling discovery of new individualized strategies against this complex syndrome.
We discovered a suggestive association between rs11265269 polymorphism near CRP gene and the risk of 
BPD. Plasma CRP shortly after birth predicts the risk of BPD. Together with the known antenatal risk factors 
rs11265269 influences susceptibility to BPD. As such, we propose that genetic and environmental factors influ-
ence the expression of CRP that may stimulate pathways predisposing to BPD.
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